Annual report pursuant to Section 13 and 15(d)

Document And Entity Information

Document And Entity Information - USD ($)
12 Months Ended
Dec. 31, 2023
Apr. 17, 2024
Jun. 30, 2023
Document Information [Line Items]      
Entity, Registrant Name PIERIS PHARMACEUTICALS, INC.    
Current Fiscal Year End Date --12-31    
Document, Fiscal Period Focus FY    
Document, Fiscal Year Focus 2023    
Document, Type 10-K/A    
Document, Annual Report true    
Document, Period End Date Dec. 31, 2023    
Document, Transition Report false    
Entity, File Number 001-37471    
Entity, Incorporation, State or Country Code NV    
Entity, Tax Identification Number 30-0784346    
Entity, Address, Address Line One 225 Franklin Street, 26th Floor    
Entity, Address, City or Town Boston    
Entity, Address, State or Province MA    
Entity, Address, Postal Zip Code 02110    
City Area Code 857    
Local Phone Number 246-8998    
Title of 12(b) Security Common Stock    
Trading Symbol PIRS    
Security Exchange Name NASDAQ    
Entity, Well-known Seasoned Issuer No    
Entity, Voluntary Filers No    
Entity, Current Reporting Status Yes    
Entity, Interactive Data, Current Yes    
Entity, Filer Category Non-accelerated Filer    
Entity, Small Business true    
Entity, Emerging Growth Company false    
ICFR Auditor Attestation Flag false    
Document, Financial Statement Error Correction Flag false    
Entity, Shell Company false    
Entity, Public Float     $ 11,222,444
Entity, Common Stock Shares, Outstanding   98,935,025  
Amendment Description Pieris Pharmaceuticals, Inc., or Company, Pieris, we, us or our, is filing this Amendment No. 1 on Form 10-K/A, the Amendment, to its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, or the Original Form 10-K Filing, which was originally filed with the Securities and Exchange Commission, or the SEC, on March 29, 2024, solely to set forth information required by Items 10, 11, 12, 13 and 14 of Part III of Form 10-K, which was intentionally omitted from the Original Form 10-K Filing. This Amendment amends and restates in its entirety Items 10, 11, 12, 13 and 14 of Part III. In addition, in accordance with Rule 12b-15 under the Securities Exchange Act of 1934, as amended, or the Exchange Act, Item 15 of Part IV of the Original Form 10-K Filing has been amended and restated solely to include as exhibits new certifications by our principal executive officer and principal financial officer.   Except as expressly set forth herein, this Amendment does not reflect facts or events occurring after the date of the Original Form 10-K Filing or modify or update any of the other disclosures contained therein in any way other than as required to reflect the amendments discussed above. Accordingly, this Amendment should be read in conjunction with the Original Form 10-K Filing and the Company’s other filings with the SEC.   On April 18, 2024, we filed a Certificate of Change with the Nevada Secretary of State effecting a reverse stock split of our authorized, issued and outstanding shares of common stock at a ratio of 1-for-80 (the “Reverse Stock Split”), which became effective on April 22, 2024. Our common stock began trading on the Nasdaq Capital Market on a reverse-split adjusted basis at the market open on April 23, 2024. As a result of the Reverse Stock Split, the number of authorized, issued and outstanding shares of our common stock immediately prior to the Reverse Stock Split was reduced into a smaller number of shares, such that every 80 shares of our common stock held by a stockholder immediately prior to the Reverse Stock Split were combined and reclassified into one share of common stock after the Reverse Stock Split. The information in this Amendment as of and for the periods prior to the effective date of the Reverse Stock Split does not give effect to the Reverse Stock Split.    
Auditor Name Ernst & Young LLP    
Auditor Location Boston, Massachusetts    
Auditor Firm ID 42    
Amendment Flag true    
Entity, Central Index Key 0001583648